Intellectus Partners’s Neurocrine Biosciences NBIX Stock Holding History

Intellectus Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,900	Closed	-$232K	–	223
2020 Q2	$232K	Buy	+1,900	New	+$210K	0.09%	195
2018 Q4	–	Sell	-1,900	Closed	-$234K	–	426
2018 Q3	$234K	Hold	1,900	–	–	0.08%	221
2018 Q2	$187K	Hold	1,900	–	–	0.07%	226
2018 Q1	$158K	Hold	1,900	–	–	0.05%	245
2017 Q4	$147K	Hold	1,900	–	–	0.05%	244
2017 Q3	$116K	Hold	1,900	–	–	0.05%	281
2017 Q2	$87K	Hold	1,900	–	–	0.04%	290
2017 Q1	$82K	Hold	1,900	–	–	0.04%	270
2016 Q4	$74K	Buy	+1,900	New	+$86K	0.04%	267

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Intellectus Partners's NBIX Position: Q3 2020 in Review

Intellectus Partners sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 1,900 shares — an estimated $232K sold.

Intellectus Partners first reported a position in NBIX in Q4 2016 and held it in 9 quarters. The position peaked at $234K in Q3 2018. 419 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

Intellectus Partners reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
Intellectus Partners sold 1,900 Neurocrine Biosciences shares in Q3 2020, an estimated $232K.
Intellectus Partners first reported a position in Neurocrine Biosciences in Q4 2016 and held it in 9 quarters.
Intellectus Partners's Neurocrine Biosciences position peaked at $234K in Q3 2018.
419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Intellectus Partners's 13F filing for Q3 2020, filed 16 Nov 2020.